P3‐061: ALLOPREGNANOLONE POTENTIATES BIOENERGETIC CAPACITY AND RESTRUCTURES MITOCHONDRIAL RETICULUM IN NEURONS AND ASTROCYTES

Abstract

We reported previously that the neurosteroid allopregnanolone (Allo) promotes neural stem cell regeneration, reverses neurogenic, metabolic and cognitive deficits and reduces Alzheimer's disease (AD) pathology in a mouse model of AD. To compare and contrast the cell-type specific mechanisms of Allo in regulating brain energy metabolism, we assessed the effect of Allo on mitochondrial bioenergetic profile and their morphological changes in rat hippocampal neurons and astrocytes. E18 rat hippocampal neurons were cultured for 10 days in neurobasal medium (NBM) with 2% B27 and then starved in 0.2% B27 / NBM for 4 hours before treatment with either 100nM Allo or 0.001% Vehicle overnight. E18 rat hippocampal astrocyte were cultured for 10 days in DMEM:F12(1:1) with 10% FBS and then starved in 10% Charcoal stripped-FBS / DMEM:F12 for 24 hours before treatment with 100nM Allo or 0.001% Vehicle overnight. Upon completion of treatment, both cell types were subject to morphological, biochemical and metabolic characterization of their mitochondrial phenotypes. In primary hippocampal neurons, Allo treatment significantly reversed nutrient deprivation-induced deficits in mitochondrial maximal- and spare respiratory capacity and dendritic morphology. In parallel, in primary hippocampal astrocytes, Allo rescued serum depletion-induced decline in mitochondrial spare respiratory capacity. Allo treatment reduced the population of less efficient swollen globule mitochondria in both neurons and astrocytes. Specifically in astrocytes, Allo decreased the number of hyperfused tubule mitochondria and increased small globule mitochondria. The effect of Allo on re-structuring nutrient or serum depletion-induced mitochondrial reticulum in both neurons and astrocytes was further supported by the restoration of the balance between Drp1 and Opa1 expression, which are key regulators for mitochondrial fission and fusion, respectively. Outcomes of our findings further support the promising therapeutic effects of Allo against bioenergetic deficits and mitochondrial inefficiency that emerge in early phases of AD, with mitochondrial dynamics being a potentially key targeted mechanism.